Regenxbio Inc. (RGNX) Given a $25.00 Price Target at Piper Jaffray Cos.
RGNX has been the topic of a number of other research reports. Zacks Investment Research upgraded Regenxbio from a sell rating to a hold rating in a report on Friday, August 26th. Chardan Capital restated a buy rating on shares of Regenxbio in a report on Monday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $26.75.
Regenxbio (NASDAQ:RGNX) traded down 1.40% during mid-day trading on Monday, reaching $17.57. 202,800 shares of the company traded hands. Regenxbio has a 52-week low of $7.07 and a 52-week high of $25.00. The company’s market capitalization is $464.99 million. The stock has a 50 day moving average price of $13.90 and a 200-day moving average price of $11.22.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. Regenxbio had a negative net margin of 451.73% and a negative return on equity of 17.89%. Analysts expect that Regenxbio will post ($2.37) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in RGNX. BlackRock Institutional Trust Company N.A. increased its position in shares of Regenxbio by 90.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 58,821 shares of the company’s stock valued at $635,000 after buying an additional 27,960 shares during the period. State Street Corp increased its position in shares of Regenxbio by 53.0% in the first quarter. State Street Corp now owns 88,025 shares of the company’s stock valued at $950,000 after buying an additional 30,500 shares during the period. Geode Capital Management LLC increased its position in shares of Regenxbio by 16.9% in the first quarter. Geode Capital Management LLC now owns 57,142 shares of the company’s stock valued at $617,000 after buying an additional 8,255 shares during the period. Sabby Management LLC increased its position in shares of Regenxbio by 157.0% in the first quarter. Sabby Management LLC now owns 300,329 shares of the company’s stock valued at $3,244,000 after buying an additional 183,469 shares during the period. Finally, Vivo Capital LLC bought a new position in shares of Regenxbio during the first quarter valued at approximately $10,697,000. Institutional investors own 68.73% of the company’s stock.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Receive News & Stock Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related stocks with our FREE daily email newsletter.